2seventy bio (TSVT) to Release Earnings on Tuesday

2seventy bio (NASDAQ:TSVT) is set to announce its earnings results before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter.

2seventy bio (NASDAQ:TSVT) last issued its earnings results on Wednesday, August 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.06. The business had revenue of $8.97 million during the quarter, compared to analysts’ expectations of $11.43 million. 2seventy bio had a negative return on equity of 66.01% and a negative net margin of 354.16%. On average, analysts expect 2seventy bio to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

2seventy bio Trading Up 4.7 %

TSVT stock traded up $0.21 during trading on Tuesday, hitting $4.72. The company had a trading volume of 168,631 shares, compared to its average volume of 771,168. The company has a fifty day moving average price of $4.74 and a two-hundred day moving average price of $4.50. 2seventy bio has a fifty-two week low of $1.53 and a fifty-two week high of $6.40. The company has a market cap of $243.08 million, a P/E ratio of -1.47 and a beta of 1.78.

Insider Activity at 2seventy bio

In other 2seventy bio news, insider Jessica Snow sold 7,816 shares of the company’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $4.32, for a total transaction of $33,765.12. Following the transaction, the insider now owns 156,330 shares of the company’s stock, valued at approximately $675,345.60. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.20% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley lowered their target price on shares of 2seventy bio from $7.00 to $6.00 and set an “equal weight” rating on the stock in a report on Monday, July 29th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.